

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-15. (Canceled)

16. (Currently amended) An isolated antibody, ~~or~~ or antigen-binding fragment thereof[[,]] that

- (a) binds to a peptide transporter and
- (b) inhibits peptide uptake into a cell expressing the peptide transporter,

wherein the antibody is human, humanized, or chimeric, and the antigen-binding fragment is human or humanized. ~~is a monoclonal or genetically engineered recombinant antibody, or antigen-binding fragment thereof.~~

17. (Previously presented) The antibody or fragment thereof of claim 16, wherein the peptide transporter is a proton motive force (PMF) dependent transporter.

18. (Previously presented) The antibody or fragment thereof of claim 16, wherein the peptide transporter is PepT1.

19. (Previously presented) The antibody or fragment thereof of claim 16, wherein the peptide transporter is PepT2.

20. (Currently amended) The antibody or fragment thereof of claim 16, wherein the antibody or fragment thereof is human. ~~monoclonal.~~

21. (Previously presented) The antibody or fragment thereof of claim 16, wherein the antibody or fragment thereof is recombinant.

22. (Currently amended) The antibody or fragment thereof of claim 16, wherein the antibody or fragment thereof is humanized ~~or chimeric~~.

23. (Currently amended) The antibody or fragment thereof of claim 16, wherein the antibody or fragment thereof is bispecific.

24. (Currently amended) A diabody that binds to a peptide transporter and inhibits peptide uptake into a cell expressing the peptide transporter, wherein the diabody is human or humanized.

25. (Previously presented) A composition comprising the antibody or fragment thereof of claim 16 and a pharmaceutically acceptable carrier, wherein the antibody or fragment thereof inhibits the growth of a cell.

26. (Previously presented) The composition of claim 25, wherein the cell is a cancer cell.

27. (Previously presented) The composition of claim 25, wherein the cell is a pancreatic cancer cell.

28. (Currently amended) A method for inhibiting peptide transporter activity, the method comprising contacting ~~the antibody or fragment thereof of claim 16~~

(a) an isolated antibody or antigen-binding fragment thereof that (i) binds to a peptide transporter and (ii) inhibits peptide uptake into a cell expressing the peptide transporter, with

(b) a cell expressing the peptide transporter,
wherein the antibody is a monoclonal or genetically engineered recombinant antibody, and
wherein the cell is *in vivo*.

29. (Previously presented) The method of claim 28, wherein the peptide transporter is a PMF dependent transporter.

30. (Previously presented) The method of claim 28, wherein the peptide transporter protein is PepT1.

31. (Previously presented) The method of claim 28, wherein the peptide transporter protein is PepT2.

32. (Previously presented) The method of claim 28, wherein the antibody is monoclonal.

33. (Cancelled)

34. (Previously presented) The method of claim 28, wherein the antibody is human or humanized.

35. (Currently amended) A method for suppressing cell growth, the method comprising contacting ~~the antibody or fragment thereof of claim 16~~ (a) an isolated antibody or antigen-binding fragment thereof that (i) binds to a peptide transporter and (ii) inhibits peptide uptake into a cell expressing the peptide transporter, with

(b) a cell expressing the peptide transporter, wherein the antibody is a monoclonal or genetically engineered recombinant antibody, the cell is *in vivo*, and growth of the cell is suppressed.

36. (Previously presented) The method of claim 35, wherein the antibody is monoclonal.

37. (Cancelled)

38. (Previously presented) The method of claim 35, wherein the antibody is human or humanized.

39. (Previously presented) The method of claim 35, wherein the peptide transporter is a PMF-dependent transporter.

40. (Previously presented) The method of claim 35, wherein the peptide transporter is PepT1.

41. (Previously presented) The method of claim 35, wherein the peptide transporter is PepT2.

42. (Previously presented) The method of claim 35, wherein the cell is a cancer cell.

43. (Previously presented) The method of claim 35, wherein the cell is a pancreatic cancer cell.

44. (New) The method of claim 28, wherein the cell is in a patient and the antibody or fragment thereof is administered to the patient.

45. (New) The method of claim 35, wherein the cell is in a patient and the antibody or fragment thereof is administered to the patient.